Abstract 10311: Atrioventricular Junctional Ablation in Patients With Atrial Fibrillation With and Without Heart Failure: A Meta-Analysis
Christian Lewinter,Eslem Sögütlü,Torsten Holm H Nielsen,John G Cleland,Lars Kober,Martin M Lewinter,cecilia M Linde,Frieder Braunschweig,Christian LewinterEslem SögütlüTorsten Holm H NielsenJohn G ClelandLars KoberMartin M Lewintercecilia M LindeFrieder BraunschweigKarolinska institute,Stockholm,SwedenAnatomi,Karolinska institute,Stockholm,SwedenHematology,Rigshospitalet,Copenhagen,DenmarkUniv of Glasgow,GlasgowRIGSHOSPITALET,CopenhagenUNIV VT UNIV OF VT MED CENTER,Burlington,VTKarolinska Institutet,Stockholm,SwedenCardiology,Karolinska institute,Stockholm,Sweden
DOI: https://doi.org/10.1161/circ.146.suppl_1.10311
IF: 37.8
2022-11-01
Circulation
Abstract:Circulation, Volume 146, Issue Suppl_1, Page A10311-A10311, November 8, 2022. Introduction:Rapid atrial fibrillation (AF) leads to heart failure (HF), but can also result from cardiac remodelling during HF. Atrioventricular junctional ablation (AVJA) cures rapid AF at the cost of permanent pacemaker dependency. We compared mortality in AF patients treated with AVJA to pharmacological therapy.Methods:We performed data searches in the PubMed, Central, and Embase till Marts 31, 2022. Inclusion criteria were observational and randomised controlled trials evaluating mortality and left ventricular ejection fraction (LVEF) in patients with AF. An exclusion criterion was lack of a parallel study design.Our primary endpoint was all-cause mortality. A secondary endpoint was the mean difference (MD) in LVEF during the follow-up. Endpoints were assessed through meta-analyses computing hazard ratios (HRs) and MDs. Mantel-Haenszel and DerSimonian random effect models were applied, respectively. LVEF<41% was used as a surrogate for HF in a sensitivity analysis.Results:Overall,1738 studies were found from the data searches. Of these, 24 fulfilled the inclusion criteria (HF, N=15). The range of age was 60-75 years and 14 to 74% were women. The follow-up time varied between 3 to 96 months. AVJA as compared with pharmacological therapy reduced all-cause mortality by 27% in patients with AF (Fig. 1), whereas the LVEF MD between groups was not significantly different (Fig. 2). In HF patients, mortality was significantly favouring AVJA as compared with pharmacological therapy (HR, 0.68; 95% confidence interval [CI], 0.51 to 0.91; P=0.009) but not for the LVEF (MD, 1.12; 95% CI, -2.90 to 5.14; P=0.54). In patients without HF, neither mortality nor the LVEF MD were significantly different between AJVA and pharmacological therapy (results not reported).Conclusion:Mortality was significantly reduced in the AVJA group as compared with the pharmacological therapy group. This benefit was only persistent in HF patients in a sensitivity analysis.
cardiac & cardiovascular systems,peripheral vascular disease